Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2199-2202

  Golden, Alyssa R ^a   Rosenthal, Margot ^a   Fultz, Ben ^a   Nichol, Kimberly A ^b   Adam, Heather J ^a,b   Gilmour, Matthew W ^a,c   Baxter, Melanie R ^a   Hoban, Daryl J ^a,b   Karlowsky, James A ^a,b   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Extensively drug resistant; Molecular characterization; Multidrug resistant; Resistance mechanisms; S. pneumoniae

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; PENICILLIN BINDING PROTEIN 2B; PENICILLIN BINDING PROTEIN 2X; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; EXTENSIVELY DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT STREPTOCOCCUS PNEUMONIAE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PHENOTYPE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; BACTERIAL GENE; CANADA; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; MULTIDRUG RESISTANCE; PNEUMOCOCCAL INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CANADA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; GENES, BACTERIAL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84939560908     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv107     Document Type: Article

References (20)

1. Linares J, Ardanuy C, Pallares R et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010; 16: 402-10.
2. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009; 30: 189-209.
3. Wierzbowski AK, Nichol K, Laing N et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998-2004). J Antimicrob Chemother 2007; 60: 733-40.
4. Nichol KA, Zhanel GG, Hoban DJ. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 3261-4.
5. Wierzbowski AK, Karlowsky JA, Adam HJ et al. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. J Antimicrob Chemother 2014; 69: 59-66.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M7-A9. CLSI, Wayne, PA, USA, 2012.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
8. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43: 699-709.
9. Louie M, Louie L, Papia G et al. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J Infect Dis 1999; 179: 892-900.
10. McEllistrem MC, Stout JE, Harrison LH. Simplified protocol for pulsedfield gel electrophoresis analysis of Streptococcus pneumoniae. J Clin Microbiol 2000; 38: 351-3.
11. Zahner D, Gudlavalleti A, Stephens DS. Increase in pilus islet 2-encoded pili among Streptococcus pneumoniae isolates, Atlanta, Georgia, USA. Emerg Infect Dis 2010; 16: 955-62.
12. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
13. Zhanel GG, Wang X, Nichol K et al. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Int J Antimicrob Agents 2006; 28: 465-71.
14. Barocchi MA, Ries J, Zogaj X et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 2006; 103: 2857-62.
15. Regev-Yochay G, Hanage WP, Trzcinski K et al. Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine 2010; 28: 4842-6.
16. Ramos V, Parra EL, Duarte C et al. Characterization of Streptococcus pneumoniae invasive serotype 19A isolates recovered in Colombia. Vaccine 2014; 32: 755-8.
17. Ardanuy C, Rolo D, Fenoll A et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 2009; 64: 507-10.
18. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-27.
19. Zhang B, Gertz RE Jr, Liu Z et al. Characterization of highly antimicrobial-resistant clinical pneumococcal isolates recovered in a Chinese hospital during 2009-2010. J Med Microbiol 2012; 61: 42-8.
20. Shin J, Baek JY, Kim SH et al. Predominance of ST320 among Streptococcus pneumoniae serotype 19A isolates from 10 Asian countries. J Antimicrob Chemother 2011; 66: 1001-4.